Workflow
哈三联(002900) - 2023 Q1 - 季度财报
MedisanMedisan(SZ:002900)2023-04-25 16:00

Financial Performance - The company's revenue for Q1 2023 was CNY 342,147,502.19, representing a 33.29% increase compared to CNY 256,694,410.27 in the same period last year[5] - Net profit attributable to shareholders reached CNY 39,163,800.70, a significant increase of 3,445.73% from a loss of CNY 1,170,560.94 in the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 20,511,251.64, up 422.73% from CNY 3,923,905.57 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.13, compared to a loss of CNY 0.02 per share in the same quarter last year, reflecting a 750.00% increase[5] - Total operating revenue for Q1 2023 reached CNY 342,147,502.19, a 33.33% increase from CNY 256,694,410.27 in Q1 2022[21] - Net profit for Q1 2023 was CNY 38,293,510.10, compared to a net loss of CNY 1,819,460.26 in the same period last year[22] - Operating profit for Q1 2023 was CNY 43,300,037.81, a significant recovery from a loss of CNY 2,724,332.84 in Q1 2022[22] Cash Flow - The net cash flow from operating activities was CNY 26,205,083.12, a turnaround from a negative CNY 7,765,583.82, marking a 437.45% improvement[5] - Cash flow from operating activities was CNY 312,367,935.53, compared to CNY 254,545,834.16 in Q1 2022, indicating improved cash generation[24] - Total cash inflow from operating activities reached ¥336,143,482.69, up from ¥260,304,215.74 in the same period last year, indicating a growth of approximately 29.1%[25] - Cash outflow from operating activities was ¥309,938,399.57, compared to ¥268,069,799.56 in Q1 2022, reflecting an increase of about 15.7%[25] - The net cash flow from investing activities was -¥43,328,299.74, a decline from a positive cash flow of ¥447,183,988.76 in Q1 2022[25] - The net cash flow from financing activities was ¥46,866,238.08, an increase from ¥26,603,539.27 in Q1 2022[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,386,123,646.22, a 3.34% increase from CNY 3,276,788,333.47 at the end of the previous year[5] - Total liabilities increased to CNY 1,295,843,183.87 from CNY 1,224,801,381.22 year-over-year[19] - The company's equity attributable to shareholders was CNY 2,079,834,612.44, up 1.92% from CNY 2,040,670,811.74 at the end of the last year[5] - Long-term investments increased to CNY 655,019,843.89, up from CNY 646,866,264.65, indicating a stable investment strategy[19] Research and Development - The company increased its investment in research and development, with development expenditures rising by 50.43% to CNY 15,898,085.31 from CNY 10,568,155.52[9] - Research and development expenses increased to CNY 20,228,682.35, up from CNY 15,964,277.61 in the previous year, reflecting a focus on innovation[21] Other Income and Expenses - The company reported a significant increase in other income, which reached CNY 11,375,287.99, a 730.23% rise from CNY 1,370,131.73 in the previous year[11] - The fair value change income was CNY 7,145,181.77, a 175.90% increase compared to a loss of CNY 9,413,631.01 in the same period last year[11] - The company paid ¥32,750,632.17 in various taxes, which is a 33.78% increase compared to the same period last year, attributed to higher revenue[12] Shareholder Information - The top shareholder, Qin Jianfei, holds 39.07% of the shares, with a total of 123,705,000 shares, indicating strong insider ownership[14]